Apolipoprotein D is associated with long-term outcome in patients with schizophrenia.
Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.
Hansen
T
T
Research Institute of Biological Psychiatry, Copenhagen University Hospital, H:S Sct. Hans Hospital, Roskilde, Denmark.
Hemmingsen
R P
RP
Wang
A G
AG
Olsen
L
L
Timm
S
S
Søeby
K
K
Jakobsen
K D
KD
Fenger
M
M
Parnas
J
J
Rasmussen
H B
HB
Werge
T
T
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001053:Apolipoproteins / Q000235:genetics*; D053399:Apolipoproteins D; D016022:Case-Control Studies; D004247:DNA / Q000032:analysis; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001053:Apolipoproteins; D053399:Apolipoproteins D; D004247:DNA